BMC Pharmacology

MEETING ABSTRACT

Open Access

Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment

Simone B Sartori*, Nigel Whittle, Alfred Hetzenauer, Nicolas Singewald

From 17th Scientific Symposium of the Austrian Pharmacological Society (APHAR). Joint meeting with the Hungarian Society of Experimental and Clinical Pharmacology (MFT) Innsbruck, Austria. 29-30 September 2011

Background

Preclinical and some clinical studies suggest a relationship between perturbation in magnesium homeostasis and pathological anxiety, although the underlying mechanisms remain largely unknown. Since there is evidence that Mg²⁺ modulates the hypothalamic-pituitary-adrenal (HPA) axis, we tested whether enhanced anxiety-like behaviour can be reliably elicited by dietary Mg²⁺ restriction and whether Mg²⁺ deficiency is associated with altered HPA axis function.

Methods

Mice assigned to Mg²⁺-deficient groups were allowed to freely access a 0.005% Mg²⁺-containing diet while control mice were fed a normal, 0.2% Mg²⁺-containing diet. The emotional behaviour of Mg²⁺-deficient mice was assessed in a battery of anxiety tests including the open field test, the light/dark test, the stress-induced hypothermia test, and the hyponeophagia test. Markers of HPA axis function including CRH gene expression and plasma ACTH levels were quantified. Neuronal activation patterns in the HPA system were investigated using mapping of the immediate early gene c-Fos as a marker of neuronal activation in response to an anxiety-provoking situation.

Results

Compared to controls, Mg²⁺-deficient mice did indeed display enhanced anxiety-related behaviour in numerous anxiety tests. The enhanced anxiety-related behaviour of

Mg²⁺-deficient mice was sensitive to chronic desipramine treatment in the hyponeophagia test and to acute diazepam treatment in the open arm exposure test. Mg²⁺ deficiency caused an increase in the transcription of corticotropin releasing hormone in the paraventricular hypothalamic nucleus (PVN), which coincided with elevated ACTH plasma levels, pointing to an enhanced set-point of the HPA axis. Chronic treatment with desipramine reversed the identified abnormalities of the stress axis. Functional mapping of neuronal activity revealed hyper-excitability in the PVN of anxious Mg²⁺-deficient mice and its normalisation through diazepam treatment.

Conclusions

Overall, the present findings demonstrate the robustness and validity of the Mg²⁺ deficiency model as a mouse model of enhanced anxiety, showing sensitivity to treatment with anxiolytics and antidepressants. It is further suggested that dysregulations in the HPA axis may contribute to the hyper-emotionality in response to dietary induced hypomagnesaemia.

Published: 5 September 2011

doi:10.1186/1471-2210-11-S2-A40

Cite this article as: Sartori *et al.*: Modulation of magnesium deficiency-induced anxiety and HPA axis dysregulation by therapeutic drug treatment. *BMC Pharmacology* 2011 11(Suppl 2):A40.

^{*} Correspondence: simone.sartori@uibk.ac.at Department of Pharmacology and Toxicology, Institute of Pharmacy, and Center for Molecular Biosciences Innsbruck (CMBI), University of Innsbruck,

